Business Wire

HANSHOW

14.8.2024 15:01:34 CEST | Business Wire | Press release

Share
Hanshow Recognized as 2024 Sample Vendor in Gartner® Hype Cycle™ Reports for Retail Technologies and Wireless Technologies

Hanshow, a global leader in developing and manufacturing electronic shelf labels (ESLs) and digital store solutions, proudly announces its recognition as a Sample Vendor in the Gartner Hype Cycle for Retail Technologies, 2024, under the Smart Shelf category, as well as in the Gartner Hype Cycle for Wireless Technology, 2024, under the Bluetooth ESL category. The Gartner Hype Cycle reports evaluate the maturity and adoption of various retail technologies, providing valuable insights for retail CIOs to make informed investment decisions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240807460853/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Hanshow‘s Holistic Green Store Solutions (Graphic: Business Wire)

According to the 2024 Hype Cycle for Retail Technologies report, “Smart shelves can provide critical real-time visibility to in-store, on-shelf availability; increase operational efficiency; guide customers and associates to discover products; and contribute inputs to Internet of Things (IoT)-based real-time store monitoring capabilities. Data from smart shelves can equip retailers to replicate a richer in-store experience, generating revenue uplift and delivering significant efficiency gains of store operations.”

Hanshow’s smart shelf technology and ESLs are positioned as high benefit innovations that are set to mature and gain widespread adoption within the next five to ten years. Hanshow’s smart shelf solutions integrate an advanced SaaS IoT management platform with devices such as ESLs and digital marketing to provide real-time inventory management, dynamic pricing, and customer engagement.

Hanshow was also recognized as a sample vendor in the 2024 Hype Cycle for Wireless Technologies under the Bluetooth ESL category. Bluetooth ESLs are highlighted by the report as a significant innovation - emerging technology with a high benefit rating and is expected to reach mainstream adoption within two to five years.

These capabilities significantly improve the efficiency of in-store operations and enhance the overall shopping experience and operational efficiency. ESLs are recognized for their ability to facilitate real-time, data-driven pricing and product information updates, crucial for retailers aiming to synchronize their digital and physical channels. Inclusion as a Sample Vendor in these Gartner Hype Cycle reports underscores Hanshow’s position as a leading innovator in the industry.

“We are honored to be recognized by Gartner as a Sample Vendor in the 2024 Hype Cycle for Retail Technologies and 2024 Hype Cycle for Wireless Technologies,” said Shiguo Hou, CEO of Hanshow. “This recognition validates our efforts in pioneering digital store solutions that help retailers optimize their operations, enhance customer engagement, and achieve sustainable growth.”

About Hanshow

Hanshow is a global leader in developing and manufacturing electronic shelf labels and digital store solutions. The company offers customers a series of customized IoT touchpoints and digital store solutions that deliver customer-centric insights. Hanshow's solutions have provided services to a vast number of stores in over 50 countries and regions, helping them streamline operations, optimize pricing strategies, and offer consumers a more personalized experience. Learn more: www.hanshow.com

Gartner Disclaimer:

Gartner, Hype Cycle for Retail Technologies, 2024, By Analysis Sandeep Unni, Max Panther Hammond, Published 29 July 2024

Gartner, Hype Cycle for Wireless Technologies, 2024, Analysis By Nick Jones, Published 5 August 2024

Gartner does not endorse any vendor, product, or service depicted in its research publications and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240807460853/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release

Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release

Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release

OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye